# HEPATITIS

# VIRAL

## Hepatitis A (ssRNA; 30–45% of acute viral hepatitis in U.S.; _MMWR_ 2018;67:1208)

• Transmission & RFs: fecal–oral route; contam. food, water, shellfish; daycare ctr; intl travel

• Incubation: 2–6 wk; no chronic carrier state

• Sx: ↓ appetite, malaise, fever, N/V, RUQ pain, jaundice; rarely ALF (↑ with chronic HCV)

• Diagnosis: acute hepatitis = ⊕ IgM anti-HAV; past exposure = ⊕ IgG anti-HAV (⊖IgM)

• Rx for acute HAV: supportive care; refer to liver txplnt center if acute liver failure

• Postexposure ppx: age 1–40 y → vaccine; age <1 y or >40 y, immunosupp, liver dis. → Ig

## Hepatitis B (dsDNA; ~45% of acute viral hepatitis in U.S.; _JAMA_ 2018;319:1802)

• Transmission: blood (IVDU, transfusion), sexual, perinatal

• Incubation: 6 wk–6 mo (mean 12–14 wk)

• Acute infxn: 70% subclinical, 30% jaundice, <1% acute liver failure (up to 60% mortality)

• Chronic infxn: HBsAg ⊕ >6 mo in <5% of adult-acquired (↑ if immunosupp), >90% of perinatal; ~40% chronic HBV → cirrhosis (↑ risk with HCV, HDV, or HIV coinfxn, EtOH)

• HCC: ↑ risk if cirrhotic, ⊕ FHx HCC, African >20 y old, Asian ♂ >40 y old or ♀ >50 y old, or >40 y old with ↑ ALT ± HBV DNA >2000. Screen with AFP & U/S q6mo.

• Extrahepatic syndromes: PAN (<1%), membranous nephropathy, MPGN, arthritis

• Serologic and virologic tests (see _Annals_ 2017;167:794 for screening guidelines)

HBsAg: appears before sx; used to screen blood donors; persists >6 mo = chronic HBV

HBeAg: evidence of viral replication and ↑ infectivity

IgM anti-HBc: 1st Ab to appear; indicates acute infection window period = HBsAg becomes ⊖, anti-HBs not yet ⊕, anti-HBc only clue to infxn

IgG anti-HBc: indicates previous (HBsAg ⊖) or ongoing (HBsAg ⊕) HBV infection

anti-HBe: indicates waning viral replication, ↓ infectivity

anti-HBs: indicates resolution of acute disease & immunity (sole marker after vaccination)

HBV DNA: presence in serum correlates with active viral replication in liver

![](https://i.imgur.com/qHbngsu.jpg)

\*Precore mutant: HBeAg not made, but anti-HBe can develop due to x-reactivity with HBcAg; a/w ↑ HBV DNA

• Rx for acute HBV: supportive; hospitalize for Δ MS or ↑ INR (liver transplant center); consider antiviral therapy if severe

![](https://i.imgur.com/QtDFcIb.jpg)

\*ALT ULN <30 U/L for ♂, <19 U/L for ♂. Adapted from _Hepatology_ 2016;63:261.

5th phase: chronic HBsAg ⊖ HBV infxn: HBeAg ⊖, anti-HBs ± ALT 正常, “occult” HBV

• Rx of chronic HBV: Rx in immune active or immune reactivation phases or cirrhotics with elevated HBV DNA or decomp. Consider liver bx if ALT 1–2× ULN or in immune tolerant phase if age >40 y; Rx if mod-to-severe inflammation or fibrosis on bx.

• **Entecavir** or **tenofovir:** nucleo(s/t)ide analogs, well tolerated, low resistance; at 5 y, HBeAg seroconversion is 30–40% & loss of HBsAg is 5–10% (_Dig Dis Sci_ 2015;60:1457; _Gastro Hep_ 2016;1:185). Tenofovir preferred if h/o lamivudine resistance.

• Rx duration: (1) HBeAg ⊕ immune active without cirrhosis: if seroconversion (HBeAg ⊖, anti-HBe ⊕), can stop after 1 y if ALT 正常 & HBV DNA suppressed or until HBsAg clears; (2) HBeAg ⊖ immune reactivation: indefinite; (3) cirrhotic: indefinite

• If undergo liver transplant: HBIG + nucleo(s/t)ide analogue effective in preventing reinfection

• HIV/HBV _coinfection:_ Rx with 2 drugs active against both HBV & HIV ([https://aidsinfo.nih.gov](https://aidsinfo.nih.gov/))

• Immunosuppression: prior to initiating chemoRx, anti-TNF, rituximab, steroids (>20 mg/d > 1 mo), screen for HBV; Rx if mod-to-high risk of reactive. (incl HBsAb ⊕ getting rituximab)

• Postexposure (risk infxn ~30%) ppx: HBIG → vaccine (if unvac or known nonresponder)

## Hepatitis C (ssRNA; ~10% of acute viral hepatitis in U.S.; _Lancet_ 2015;385:1124)

• Transmission: blood (IVDU, transfusion rare cause) > sexual; 20–30% without clear precipitant

• Incubation: 1–5 mo; mean 6–7 wk

• Acute infxn: 80% subclinical; 10–20% sx hepatitis with jaundice; acute liver failure rare; prob of spont clearance a/w _IL28B_ & HLA class II genotypes (_Annals_ 2013;158:235)

• Chronic: up to 85% → chronic hepatitis, 20–30% of whom develop cirrhosis (after ~20 y)

↑ risk of cirrhosis in men, EtOH, HIV; HCC in 1–4% of cirrhotics/y

• Extrahepatic syndromes: mixed cryoglobulinemia, porphyria cutanea tarda, lichen planus, leukocytoclastic vasculitis, thyroiditis, MPGN, IPF, NHL and monoclonal gammopathies

• Serologic, virologic, & genetic tests

anti-HCV (ELISA): ⊕ in 6 wk, does _not_ = recovery or immunity; can be ⊖ after recovery

HCV RNA: ⊕ within 2 wk, marker of active infection

HCV genotype (1–6): guides duration & predicts response to Rx; geno. 3 a/w ↑ risk HCC

• Dx: _acute_ hepatitis = ⊕ HCV RNA, ± anti-HCV; _resolved_ = ⊖ HCV RNA, ± anti-HCV; _chronic_ = ⊕ HCV RNA, ⊕ anti-HCV

• 治療 indications ([www.hcvguidelines.org](http://www.hcvguidelines.org/)) (_Hep_ 2018;68:827; _Lancet_ 2019;393:1453)

Acute: if no spont. clearance at 12–16 wk, can Rx with same regimens for chronic HCV

Chronic: ↓ HCC & mortality. Recommended for all except if ↓ life expectancy.

<table><colgroup><col> <col></colgroup><tbody><tr><td colspan="2"><p><b>Recommended Oral Direct-Acting Antiviral (DAA) Regimens</b></p></td></tr><tr><td><p>Regimen</p></td><td><p>Indication</p></td></tr><tr><td><p>sofosbuvir &amp; ledipasvir</p></td><td><p>Genotypes 1 and 4</p></td></tr><tr><td><p>grazoprevir &amp; elbasvir</p></td><td><p>Genotypes 1 and 4</p></td></tr><tr><td><p>sofosbuvir &amp; daclatasvir</p></td><td><p>Alternative for genotypes 1–4</p></td></tr><tr><td><p>sofosbuvir &amp; velpatasvir</p></td><td><p>Genotypes 1–6</p></td></tr><tr><td><p>sofosbuvir, velpatasvir, &amp; voxilaprevir</p></td><td><p>DAA-experienced genotypes 1–6</p></td></tr><tr><td><p>glecaprevir &amp; pibrentasvir</p></td><td><p>Genotypes 1–6, DAA-experienced genotype 1</p></td></tr><tr><td colspan="2"><p>Individual components: <i>RNA polymerase inhibitor</i> (“…buvir”); <i>NS5a inhibitor</i> (“…asvir”); <i>NS3/4A protease inhibitor</i> (“…previr”)</p></td></tr></tbody></table>

Based on the American Association for the Study of Liver Diseases/Infectious Diseases Society of America 2018 Guidance. [www.hcvguidelines.org](http://www.hcvguidelines.org/). _Clin Infect Dis_ 2018;67:1477

• Monitoring on Rx: CBC, INR, LFTs, GFR, HCV VL prior to starting Rx. PIs contraindicated if decomp. liver dx (ascites, encephalopathy) or CTP score ≥7. D/c Rx if jaundice, N/V, weakness, 10x ↑ in ALT, or significant ↑ in bili, Aϕ, INR after 4 wk.

• Goal is _sustained virologic response_ (SVR) = ∅ viremia 12 wk after completion of Rx. Success depends on genotype but SVR rates >90% with current regimens.

• Special populations (HCV/HIV coinfection, decompensated cirrhosis, s/p liver transplant, renal impairment): [www.hcvguidelines.com](http://www.hcvguidelines.com/) for updated recs on mgmt

• Vaccinate all chronic HCV patients against HBV and HAV if not immune

• Postexposure (needlestick risk ~3%) ppx: none, although sofosbuvir-velpatasivir under investigation in 臨床trial; if HCV RNA → ⊕, consider Rx within 3 mo

## Hepatitis D (RNA)

• Transmission: blood or sexual; endemic in Africa & E. Europe. Generally requires host to already have HBV infxn in order to cause co-infection or superinfection; in rare cases (immunosupp s/p liver txplt) can replicate autonomously.

• Natural hx: acute HBV-HDV coinfection resolves in >80% of cases; however acute HDV superinfection leads to chronic HBV-HDV in most cases (↑ progression to cirrhosis, HCC)

## Hepatitis E (ssRNA; _World J Gastro_ 2016;22:7030; _Gastro Clin N Am_ 2017;46:393)

• Most common cause of acute viral hepatitis in endemic areas

• Transmission: fecal–oral; travelers to central & SE Asia, Africa and Mexico, exp. to swine. ↑ rates of cases in Europe.

• Natural hx: acute hepatitis with ↑ mort. (10–20%) if pregnant; rare chronic in transplant 病人

• Dx: IgM anti-HEV (through CDC), HEV RNA

• Extrahepatic sx: arthritis, pancreatitis, anemia, neuro (GBS, meningoencephalitis)

Other viruses (human pegivirus, CMV, EBV, HSV, VZV)

# AUTOIMMUNE HEPATITIS (AIH)

## Classification (_J Hep_ 2015;62:S100, _World J Gastro_ 2015;21:60)

• Type 1: anti-smooth muscle Ab (ASMA), ANA; anti-soluble liver antigen (anti-SLA), a/w more severe disease and relapsing disease

• Type 2: anti-liver/kidney microsome 1 (anti-LKM1); anti-liver cytosol type 1 (ALC-1);

• Overlap syndrome: AIH + PBC (suspect if ⊕ antimitochondrial Ab or ⊕ histology → “autoimmune cholangitis”) or PSC (suspect if ↑ Aφ, IBD, pruritus, or ⊕ radiology/histology)

• Drug-induced: minocycline, nitrofurantoin, infliximab, hydralazine, α-methyldopa, statins

## Diagnosis and 治療 (_J Hepatol_ 2015;63:1543, _Clin Liver Dis_ 2015;19:57)

• 70% female; 40% present with severe AIH (3% ALF) with ALT >10 × ULN; 34–45% asx

• Extrahepatic syndromes: thyroiditis, arthritis, UC, Sjögren’s, Coombs’ ⊕ hemolytic anemia

• Dx: scoring system combining serologies, ↑ IgG, ∅ viral hepatitis, & liver bx (interface hepatitis & lymphoplasmacytic infiltrate) has high Sp & mod Se (_Dig Dis_ 2015;33\[S2\]:53)

• Rx: (1) ALT 10× ULN; (2) ALT 5× ULN & IgG 2× ULN; or (3) bridging/multiacinar necrosis

• Induction Rx: (1) prednisone monoRx; (2) prednisone + AZA, or (3) budesonide (if non-cirrhotic) + AZA → 65–80% remission (asx, 正常 LFTs, bili, & IgG, none-to-minimal interface hepatitis); taper steroids as able; relapse rate of 50–80% (_J Hep_ 2015;62:S100)

• Nonresponders or AZA intolerant: cyclosporine, tacrolimus, MMF, rituximab, infliximab

• HCC screening and liver transplant referral for ESLD

# OTHER CAUSES OF HEPATITIS OR HEPATOTOXICITY

## Alcoholic hepatitis (_J Hepatol_ 2016;69:154; _Am J Gastro_ 2018;113:175)

• Sx: progressive jaundice, tender hepatomegaly, fever, ascites, GIB, encephalopathy

• Labs: ALT usually <300–500 with AST:ALT > 2:1, ↓ plt, ↑ Tbili & INR indicate severe hepatitis

• Prognosis: scoring systems include Maddrey’s discriminant fxn (MDF), Lille model, MELD

MDF (4.6 × \[PT – control\] + Tb) ≥32 with 30–50% 1-mo mortality if unRx’d (_Gastro_ 1996;110:1847)

Lille model: predicts nonresponse to steroids after 1st week of Rx; score >0.45 predicts poor response to further steroid Rx and a/w ↓ in 6-mo survival (_Hep_ 2007;45:1348)

Combination of Lille + MELD scores best predictor of mortality (_Gastro_ 2015;149:398)

• Rx: consider if MDF ≥32, MELD >18, or presence of encephalopathy

Steroids (eg, methylprednisolone 32 mg/d or prednisolone 40 mg/d × 4 wk → 4–6 wk taper) may ↓ 1-mo but not 6-mo mortality, a/w ↑ infection (_NEJM_ 2015;372:1619, CD001511)

Contraindic.: active GIB, pancreatitis, untreated HBV, uncontrolled bact/fungal/TB infxn

Addition of NAC to steroids ↓ 1-mo but not 6-mo mortality (_NEJM_ 2011;365:1781)

• Consider early transplantation in carefully selected 病人 (_Gastro_ 2018;155:422)

## Acetaminophen hepatotoxicity _(Clin J Transl Hepatol_ 2016;4:131; _BMJ_ 2016;353:i2579)

• 病生理: >90% of acetaminophen (N-acetyl-p-aminophenol, APAP) metab into nontoxic metab, but ~5% metab by CYP2E1 into NAPQI, a hepatotoxic metab detoxified by glutathione conjugation; APAP overdose (>10 g) depletes glutathione stores → injury

• CYP2E1 _induced_ by fasting, alcohol, and certain anticonvulsants and anti-TB drugs, resulting in a “therapeutic misadventure” with even low doses (2–6 g) of acetaminophen

• Liver dysfunction may not be apparent for 2–6 d

• Rx: NG lavage, activated charcoal if within 4 h. Consider early transfer to transplant ctr

**_N_\-acetylcysteine:** administer up to 72 h after ingestion, if time of ingestion unknown or chronic ingestion >4g/d; low threshold to start NAC with low or undetectable APAP levels

PO NAC (preferred): 140 mg/kg loading dose → 70 mg/kg q4h × 17 additional doses

IV NAC: 150 mg/kg × 1 h → 50 mg/kg × 4 h → 100 mg/kg × 16 h; risk of anaphylaxis (↓ with 12-h regimen; _Lancet_ 2014;383:697); use if unable to tolerate POs, GIB, pregnancy, ALF

## Ischemic hepatitis

• “Shock liver” with AST & ALT >1000 + ↑↑ LDH (ALT:LDH ratio often <1.5); delayed ↑↑ Tbili

• Seen in HoTN & CHF; often requires ↑ venous + ↓ portal/arterial pressure + hypoxia

Nonalcoholic fatty liver disease (NAFLD) (_NEJM_ 2017;377:2063)

• 定義: fatty infiltration of liver _and_ absence of EtOH or other cause of steatosis

### NAFL = steatosis, ∅ inflam; **NASH** = steatosis + inflam ± fibrosis on bx

• NAFLD: 10–30% of U.S. pop. & over 60% in T2DM & obesity

• NASH: 2–5% of NAFLD & risk of cirrhosis in NASH with fibrosis on bx is 30% at 10 y

• Clinical: 80% asx, ↑ ALT > AST, but 正常 ALT/AST does not exclude poss. of NASH on bx

• Dx: liver bx remains gold standard. VCT elastography emerging modality (_J Hepatol_ 2017;66:1022). NAFLD fibrosis score predicts NASH with advanced fibrosis with PPV >80%

• Rx: wt loss (ideally ≥10% to reverse fibrosis, _Gastro_ 2015;149:367), exercise, DM control, liraglutide (_Lancet_ 2016;387:679) or pioglitazone (even without DM), statins (_Metabolism_ 2017;71:17); vit E ↓ steatosis but not fibrosis in 病人 without DM (_Hepatol_ 2018;67:328)

• HCC a complication of NAFLD, usually but not always in setting of NASH cirrhosis
